# Ensemble Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ensemble-discovery

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.ensemblediscovery.com
- Total disclosed funding: $30M
- Latest round: Series B (Jun 1, 2007)
- Investors on record: 5

## About

Ensemble Discovery Corp. focuses on developing innovative therapeutics and bioassays through its proprietary DNA-Programmed Chemistry™ platform, facilitating drug discovery and biodetection for researchers in academia and the biotech industry.Ensemble Discovery Corp. operates in the field of pharmacological and diagnostic solutions. The company is headquartered in Cambridge, US. It has successfully raised a total of USD 5.00 mn through its latest funding round, Series B, led by Flagship Pioneering and Oxford Bioscience Partners, which brought the current company valuation to USD 43.77 mn. The firm has completed four successful deals to date.Ensemble Discovery specializes in the development of innovative therapeutics and bioassays utilizing its proprietary DNA-Programmed Chemistry™ (DPC™) platform. This platform enables precise control over chemical reactivity, facilitating the synthesis of diverse compounds for drug discovery and biodetection applications. Key product offerings include Programmed Macrocycles™, aimed at addressing historically challenging targets in the therapeutic space, and Programmed Bioassays™, which generate signaling molecules to assess protein functionality in biological assays. The primary end users of these products comprise researchers in academia and industry focused on drug development and diagnostics in various fields, including oncology and molecular biology. The company's offerings are designed to meet the needs of customers in global markets, particularly in North America and Europe, where advanced research and clinical diagnostics are prevalent.Ensemble Discovery's revenue model centers around the sale of its specialized products and services to research institutions and corporate clients in the pharmaceutical and biotechnology sectors. The firm's transactions typically involve B2B agreements, where clients purchase proprietary assays or reagents for specific research purposes, alongside potential collaborations for product development. Revenue generation may include arrangements for large-scale supply contracts or partnerships, particularly for flagship products such as its Programmed Bioassays™ and detection systems for nucleic acids and proteins. These offerings are intended for high-volume use in both research and clinical diagnostic settings, providing Ensemble Discovery with a robust client base that values advanced technological solutions for complex biological analyses.Ensemble Discovery Corp. is focused on launching new products aimed at enhancing its therapeutic platform and expanding its bioassay offerings. The company is exploring entry into new markets in Asia and Europe, with plans for expansion by the end of 2024. The recent funding through the Series B round will be strategically utilized to support these product development initiatives and market expansion efforts.

## Funding rounds

- Series B, Jun 1, 2007, $5M — Flagship Pioneering, Oxford Bioscience Partners
- Series B, Jan 31, 2007, $10M — ARCH Venture Partners, Flagship Pioneering, Oxford Bioscience Partners, Presidio Partners, 180 Degree Capital
- Series A, May 12, 2004, $15M — ARCH Venture Partners, Flagship Pioneering, Oxford Bioscience Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series B
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series B